查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1941605

植入式藥物輸送裝置市場規模、佔有率、趨勢及預測（依產品類型、技術、應用、最終用戶及地區分類），2026-2034年

Implantable Drug Delivery Devices Market Size, Share, Trends and Forecast by Product Type, Technology, Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年全球植入式藥物輸送裝置市場規模為162億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到280億美元，2026年至2034年的複合年成長率（CAGR）為6.25%。北美目前佔據市場主導地位，預計2025年將佔據超過40.7%的市場。人工智慧（AI）智慧感測器、可生物分解材料以及微型化長效植入的日益普及，正在推動市場成長。此外，即時給藥演算法和雲連接提高了給藥精度並減少了用藥錯誤，而可生物分解系統無需手術取出，從而拓寬了治療應用範圍。微型化長效植入有助於提高慢性病患者的用藥依從性，並為門診治療提供支援。此外，主要企業不斷增加的研發投入、臨床試驗的進展以及新產品推出，都促進了植入式藥物輸送裝置市場佔有率的擴大。

全球植入式藥物輸送裝置市場主要受多種關鍵因素驅動，其中最主要的是慢性病病例的激增，包括心血管疾病、糖尿病和癌症。此外，對微創手術和治療的需求不斷成長，以及易患慢性病的老年人口顯著增加，也顯著推動了市場擴張。同時，全球對植入式裝置技術進步的關注，例如可程式設計和可生物分解藥物傳輸系統的設計，以及對永續治療方案日益成長的需求，也促進了植入式藥物輸送裝置市場佔有率的擴大。此外，醫療保健產業降低成本的需求不斷成長，以及便利的報銷政策，也顯著影響市場成長。因此，多個國家的政府目前正在實施相關政策，以促進醫療保健領域的先進技術發展，進而提振全球市場需求。此外，旨在開發創新植入式藥物輸送裝置的研發活動的顯著增加，也對市場動態產生了影響。其他重要因素包括人們對植入式藥物輸送裝置益處的認知不斷提高，以及對標靶藥物輸送和個人化醫療的高度重視，這些都極大地促進了植入式藥物輸送裝置市場的成長。

由於慢性病高發生率以及對創新醫療解決方案的高度重視，美國是植入式藥物輸送裝置的主要市場。例如，糖尿病、心臟病和癌症等慢性病是美國殘疾和死亡的主要原因，每年造成4.5兆美元的國民醫療支出。此外，美國成熟的製藥和醫療設備產業正在推動這些裝置的研發和廣泛應用。領先的研發舉措和有利的法規環境也為該市場的成長提供了支持。此外，對標靶治療和個人化醫療日益成長的需求，以及對改善患者療效的迫切需要，都促進了植入式藥物輸送裝置在美國的普及，從而推動了市場擴張和創新。

植入式藥物輸送裝置市場趨勢：

將人工智慧 (AI) 和智慧感測器整合到個人化藥物傳輸中

植入式藥物傳輸裝置的市場成長正因人工智慧（AI）的融合和智慧感測器技術的進步而改變。此外，研發投入正不斷增加，用於先進感測器的微型化和無線供電技術。最新的智慧型幫浦配備了AI驅動的演算法，能夠以每秒一次的間隔處理患者數據，從而實現即時劑量調整。雲端連接支援遠端醫療管理，使臨床醫生無需面對面會診即可更改治療通訊協定。研究表明，這些系統透過最佳化劑量控制，可將用藥錯誤減少15%至25%。科學文獻表明，具有自動交換機制的智慧型輸液裝置可顯著提高給藥的連續性和準確性。研究表明，自動促效劑交換系統可在無需人工評估的情況下維持穩定的治療水準。此外，各公司正在推出各種穿戴式智慧健康感測器。 2024年，華為TruSense系統發布，為使用者提供精準、科學的健康和健身技術。

可生物分解和可生物吸收的材料為設備設計帶來創新。

生物可分解材料正在從根本上改變植入式設備的設計，無需手術取出。科學家開發出可植入的生物可分解摩擦奈米發電機，可透過無線超音波活化產生電脈衝。這些設備透過電場輸送抗有絲分裂藥物，同時抑制癌細胞中的微管組裝。治療結束後，這些設備會完全分解，無需二次取出手術。美國國立衛生研究院 (NIH) 的 2025 DEBUT 挑戰計畫透過專案資助計畫支持生物可分解植入的創新。材料方面的進步包括生物相容性聚合物，這些聚合物在治療過程中保持結構完整性，並在治療後安全溶解。研究人員正在探索絲素蛋白和生物可分解彈性體在壓力感測器和藥物儲存中的應用。這些材料具有可控的分解特性，同時最大限度地減少異物反應。產學研合作已研發出硬幣大小的生物感測器，其佩戴舒適度和精度均已提升。生物可分解能源採集電源無需手術更換電池。這項技術可用於術後恢復和急性期治療的暫時植入。 2024年，全球醫療技術領導者史賽克公司宣佈在印度推出InSpace，這是首款用於關節鏡治療大規模不可修復性肩迴旋肌斷裂（MIRCT）*的球囊植入。 MIRCT是肩關節疾病的主要原因之一。 <sup>1,2,3</sup> InSpace為外科醫生在肩關節治療領域提供了新的選擇，幫助他們更有效地滿足患者的需求。

用於慢性疾病管理的微型長效植入

微型化技術使得火柴棒大小的植入能夠持續釋放藥物六個月至一年。 Vivani Medical 的 GLP-1Exenatide植入在 LIBERATE-1 試驗中迅速招募了 24 名受試者，僅花了四周時間。這種皮下植入裝置旨在解決慢性病患者用藥依從性差的問題，而這問題影響著 50% 的慢性疾病患者。植入能夠維持穩定的藥物濃度，避免注射帶來的波動。此外，重量不足 45 克的緊湊型幫浦能夠實現 0.05 毫升/小時的微量給藥精度。最新裝置採用磁感應充電技術，可在 10-20 毫米的組織深度內進行非侵入性能量傳輸。臨床數據顯示，六個月的植入能夠提高患者的用藥依從性，同時減少就診次數。目前，該技術正著眼於將其應用於糖尿病和肥胖症的治療，以實現每年一次的給藥方案。這項技術對於難以進行日常藥物管理的年長患者尤其有益。隨著植入式藥物輸送裝置的微型化技術使得門診手術成為可能，從而降低了醫療成本，該領域的市場成長正在加速。企業報告稱，與每日服藥相比，患者更傾向於選擇長效植入。

目錄

第1章：序言

第2章：調查範圍與調查方法

  • 調查目標
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章 引言

5. 全球植入式藥物傳輸裝置市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 按產品類型分類的市場區隔

  • 植入式藥物釋放型支架
  • 植入式避孕藥物輸送裝置
  • 植入式眼內藥物輸送裝置
  • 植入式近距離放射種子裝置
  • 植入式藥物輸送幫浦裝置

第7章 按技術分類的市場區隔

  • 可生物分解植入
  • 不可生物分解的植入

第8章 按應用分類的市場細分

  • 腫瘤學
  • 循環系統疾病
  • 自體免疫疾病
  • 婦產科
  • 其他

第9章 依最終用戶分類的市場細分

  • 醫院
  • 門診手術中心
  • 其他

第10章 按地區分類的市場細分

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 促進因素、限制因素與機遇

第12章 價值鏈分析

第13章 波特五力分析

第14章：定價分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Delpor Inc.
    • Koninklijke DSM NV
    • Medtronic plc
    • Theragenics Corporation
Product Code: SR112026A8302

The global implantable drug delivery devices market size was valued at USD 16.2 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 28.0 Billion by 2034, exhibiting a CAGR of 6.25% during 2026-2034. North America currently dominates the market, holding a significant market share of over 40.7% in 2025. The heightened usage of artificial intelligence (AI)-enabled smart sensors, biodegradable materials, and miniaturized long-acting implants is supporting the market growth. Additionally, real-time dosing algorithms and cloud connectivity improve accuracy and cut medication errors, while biodegradable systems eliminate removal surgeries and expand therapeutic applications. Miniaturized, long-duration implants enhance adherence in chronic disease management and support outpatient care. Furthermore, the growing research and development (R&D) investments, clinical trial progress, and new product launches from leading companies are expanding the implantable drug delivery devices market share.

The global implantable drug delivery devices market is principally bolstered by numerous critical factors, majorly encompassing the burgeoning cases of chronic conditions, which generally include cardiovascular issues, diabetes, or cancer. Besides this, the amplifying requirement for minimally invasive surgeries or procedures and the notable boost in geriatric population, which is comparatively more prone to chronic disorders, are significantly fueling market expansion. In addition to this, global focus on technological enhancements in implantable devices, like the designing of programmable or biodegradable drug delivery systems, and the accelerating need for prolonged therapeutic solutions are expanding the implantable drug delivery devices market share. Apart from this, the bolstering necessity to lower expenditure in healthcare landscape and the easy accessibility of profitable reimbursement regulations are impacting the market growth intensely. In line with this, governments of several countries are currently launching ventures to incentivize leading-edge technologies for healthcare, which, as a consequence, is heightening the market demand worldwide. Moreover, the significant elevation in research and development (R&D) efforts targeted at launching innovative and novel implantable drug delivery devices are also influencing market dynamics. Other pivotal factors, enveloping the magnifying consciousness associated with the advantages of utilizing implantable drug delivery devices along with the robust emphasis on targeted drug delivery as well as personalized medicine, are notably contributing to the implantable drug delivery devices market growth.

The United States is a prominent market for implantable drug delivery devices, driven by a high prevalence of chronic diseases and a strong focus on innovative healthcare solutions. For instance, according to the chronic diseases, including diabetes, heart conditions, and cancer, are the major causes of both disability and death across the U.S., accounting for USD 4.5 trillion annually in nation's health care expenditure. Moreover, the country's well-established pharmaceutical and medical device industries facilitate the development and adoption of these devices. Furthermore, advanced research and development initiatives, coupled with a favorable regulatory environment, support the growth of this market. Additionally, the increasing demand for targeted and personalized therapies, as well as the need for improved patient outcomes, contribute to the rising adoption of implantable drug delivery devices in the United States. This fuels market expansion and innovation.

Implantable Drug Delivery Devices Market Trends:

Integration Of Artificial Intelligence (AI) and Smart Sensors for Personalized Drug Delivery

The implantable drug delivery devices market growth is experiencing transformation through AI integration and smart sensor technologies. Moreover, there is an increase in research and development (R&D) investments for advanced sensor miniaturization and wireless power capabilities. Modern smart pumps incorporate AI-driven algorithms processing patient data at one-second intervals for real-time dosage adjustments. Cloud connectivity enables remote therapy management with clinicians modifying treatment protocols without physical consultations. Research demonstrates these systems reduce medication errors by 15-25% through optimized dosage control. Scientific publications confirm smart infusion devices with automated replacement mechanisms significantly enhance drug delivery continuity and accuracy. Studies showed automated vasoactive drug replacement systems maintaining consistent therapeutic levels while eliminating manual assessment requirements. Furthermore, companies are launching various smart health sensors in the form of wearables. In 2024, HUAWEI TruSense System was launched which provided accurate and science-based health and fitness technology to users.

Biodegradable And Bioresorbable Materials Revolutionizing Device Design

Biodegradable materials are fundamentally changing implantable device architectures eliminating surgical removal requirements. Scientists developed implantable biodegradable triboelectric nanogenerators generating electrical stimulation through wireless ultrasound activation. These devices deliver anti-mitotic drugs while disrupting cancer cell microtubule assembly through electrical fields. Complete device degradation occurs post-therapy without secondary extraction procedures. NIH's 2025 DEBUT Challenge supports biodegradable implant innovations through targeted funding programs. Material advances include biocompatible polymers maintaining structural integrity during therapy then safely dissolving. Research explores silk fibroin proteins and biodegradable elastomers for pressure sensors and drug reservoirs. These materials minimize foreign body reactions while providing controlled degradation profiles. Academic-industry collaborations delivered coin-sized biosensors with enhanced wearability and accuracy. Biodegradable power sources using energy harvesting eliminate battery replacement surgeries. The technology enables temporary therapeutic implants for post-surgical recovery or acute condition management. In 2024, Stryker, a worldwide leader in medical technology, declared the introduction of InSpace, the initial balloon implant designed for arthroscopic treatment of massive irreparable rotator cuff tears (MIRCTs)*, in India. MIRCTs are among the leading factors contributing to shoulder problems. 1,2,3 InSpace offers a fresh alternative for surgeons in the shoulder care continuum, helping them address their patients' needs more effectively.

Miniaturized Long-Acting Implants for Chronic Disease Management

Miniaturization technologies enable matchstick-sized implants delivering medications for six months to one year. Vivani Medical's GLP-1 exenatide implant achieved rapid LIBERATE-1 trial enrollment with 24 subjects recruited within four weeks. The subdermal device addresses medication non-adherence affecting 50% of chronic disease patients. The implant maintains consistent drug levels avoiding peaks and troughs associated with injections. Moreover, miniaturized pumps weighing under 45 grams deliver micro-doses at 0.05 mL/hour precision. Modern devices incorporate magnetic induction charging through 10 to 20mm tissue depth enabling non-invasive power transfer. Clinical evidence demonstrates six-month implants reducing hospital visits while improving adherence rates. Development focuses on once-yearly administration possibilities for diabetes and obesity management. The technology particularly benefits elderly patients struggling with daily medication regimens. Implantable drug delivery devices market growth accelerates as miniaturization enables outpatient procedures reducing healthcare costs. Companies report a higher percentage of patient preference for long-acting implants over daily medications.

Implantable Drug Delivery Devices Industry Segmentation:

Analysis by Product Type:

  • Implantable Drug Eluting Stents
  • Implantable Contraceptive Drug Delivery Devices
  • Implantable Intraocular Drug Delivery Devices
  • Implantable Brachytherapy Seeds Devices
  • Implantable Drug Delivery Pump Devices

Implantable drug eluting stents lead the market with around 32.2% of market share in 2025, driven by their role in preventing restenosis in coronary arteries. These devices are designed to release drugs directly at the site of arterial blockages, reducing the risk of re-narrowing after stent implantation. The integration of drug-eluting technology with stents enhances the efficacy of cardiovascular treatments, addressing critical challenges in managing coronary artery disease. The growing prevalence of heart-related conditions, coupled with advancements in stent design and drug formulations, is fueling market growth. Additionally, the shift toward minimally invasive procedures and the increasing preference for DES over bare-metal stents, due to their reduced risk of complications, further supports market expansion. As the demand for more effective treatments rises, implantable drug-eluting stents continue to dominate as a leading choice in the cardiovascular sector.

Analysis by Technology:

  • Biodegradable Implants
  • Non-Biodegradable Implants

Non-biodegradable leads the market in 2025. These devices are designed to release therapeutics over extended periods, offering controlled and sustained release without the need for frequent re-administration. Non-biodegradable systems, often used in the treatment of chronic conditions such as diabetes, cancer, and pain management, are durable and provide long-term therapeutic benefits. These devices typically include materials like metals, polymers, or ceramics, which ensure stability and longevity in the human body. Additionally, the demand for non-biodegradable drug delivery systems is driven by their ability to maintain consistent drug levels, improving patient compliance and reducing the need for repeated interventions. With advancements in materials science and device engineering, the market for non-biodegradable systems is expected to grow, offering significant potential for pharmaceutical companies seeking to enhance therapeutic delivery while minimizing side effects.

Analysis by Application:

  • Oncology
  • Cardiovascular
  • Autoimmune Diseases
  • Obstetrics and Gynecology
  • Others

Cardiovascular leads the market in 2025 by application, driven by the widespread occurrence of heart-related conditions and the growing need for advanced and effective treatment options. Devices used in cardiovascular applications, such as drug-eluting stents and pacemakers, play a crucial role in managing conditions like coronary artery disease, arrhythmias, and heart failure. The growing aging population, coupled with unhealthy lifestyle habits, has contributed to an increase in cardiovascular diseases, driving demand for innovative therapeutic solutions. Implantable drug delivery systems in this category enable precise medication release, which enhances treatment effectiveness, minimizes potential complications, and contributes to better patient outcomes. Furthermore, technological advancements in the design and material properties of cardiovascular devices are contributing to the growth of this segment. As healthcare systems focus on improving heart disease management, cardiovascular applications will remain at the forefront of market development.

Analysis by End User:

  • Hospitals
  • Ambulatory Surgery Centers
  • Others

Hospitals lead the market in 2025, accounting for a significant share due to their central role in patient treatment and care. Hospitals are primary settings for the implantation of drug delivery systems, particularly for patients requiring specialized procedures like stent placement or pain management devices. These institutions benefit from the latest innovations in implantable devices, offering targeted therapies for chronic conditions such as diabetes, cancer, and cardiovascular diseases. Additionally, hospitals are equipped with advanced medical technologies and skilled professionals necessary for the successful administration and monitoring of these devices. With the ongoing enhancement of healthcare infrastructure worldwide, hospitals continue to serve as the primary users of implantable drug delivery systems. Furthermore, their ability to integrate new technologies into routine care, combined with rising patient volumes and the increasing complexity of treatments, ensures that hospitals will continue to dominate the market share in the years to come and will contribute to a positive implantable drug delivery devices market outlook.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 40.7%. This region is chiefly influenced by highly robust healthcare ecosystem, substantial efforts and investments pertaining to research and development programs, and elevated requirement for cutting-edge treatment methodologies. The region heavily profits from resilient regulatory aid, facilitating quick utilization leading-edge technologies. In addition to this, the establishment of leading pharmaceutical firms and device producers in Canada as well as the United States further prompts significant growth in this market, with an active emphasis on enhancing patient outcomes by leveraging targeted therapies. Besides this, the magnification of chronic diseases prevalence, for instance cancer, diabetes, or cardiovascular disorders, is escalating requirement for implantable drug delivery methods. For instance, as per industry reports, in 2024, around 70% of individuals in Canada were suffering from type 2 diabetes, while 90% of individuals were suffering from type 1 diabetes. Furthermore, North America's well-structured reimbursement policy framework and boosting awareness regarding the profits of implantable systems also strengthens its domination in the global industry, prompting constant innovations in this segment.

Key Regional Takeaways:

United States Implantable Drug Delivery Devices Market Analysis

The United States drives global innovation through FDA's progressive regulatory approach balancing safety with timely market access. Orchestra BioMed received IDE approval in 2025 initiating a 740-patient pivotal trial for Virtue SAB. The sirolimus-angioinfusion balloon addresses coronary restenosis affecting 325,000 patients annually. FDA breakthrough designations expedite development timelines for devices addressing unmet medical needs. Government healthcare programs including Medicare provide coverage for approved implantable devices supporting market growth. Academic medical centers conduct pioneering research advancing drug delivery technologies through federal grants. The country hosts headquarters of major device manufacturers investing billions in R&D annually. Clinical trial infrastructure supports rapid patient enrollment accelerating product development cycles. Specialized manufacturing facilities produce implantable devices meeting stringent quality requirements. Healthcare provider training programs ensure proper device implantation and patient management protocols.

Europe Implantable Drug Delivery Devices Market Analysis

European markets demonstrate strong adoption driven by universal healthcare systems prioritizing cost-effective chronic disease management. Strategic partnerships between pharmaceutical and device companies accelerate innovation in drug-device combinations. Government initiatives promote digital health transformation integrating smart implantable devices into care pathways. Nordic countries lead adoption rates with comprehensive reimbursement covering advanced drug delivery systems. Research consortiums combining academic and industry partners receive EU funding for collaborative projects. Regulatory harmonization across member states simplifies multi-country clinical trials and market launches. Patient advocacy groups influence policy decisions supporting access to innovative implantable therapies. In 2025, Roche announced that it has obtained the EU CE mark for its Port Delivery Platform with Susvimo, to be marketed in the EU as Contivue(R). The system consists of the implantable device through which Susvimo is administered, and four supportive devices used to initially fill, insert, refill, and remove the implant (if needed). Susvimo(R) (ranibizumab injection) 100 mg/mL for intravitreal use via the Susvimo eye implant is currently under review with the European Medicines Agency (EMA) for the treatment of nAMD. With immediate and predictable durability, Contivue with Susvimo provides continuous delivery of a customized formulation of ranibizumab directly to the eye.

Asia Pacific Implantable Drug Delivery Devices Market Analysis

Asia Pacific emerges as the fastest-growing region driven by massive diabetic populations requiring advanced management solutions. China's diabetes market is projected to attain USD 9.81 Billion by 2033 according to the predictions of IMARC Group. Government healthcare reforms expand insurance coverage for implantable devices improving patient access. Joint ventures between international and local companies facilitate technology transfer and market entry. The rise in disposable income among Indians also drives the demand for premium healthcare including advanced drug delivery options. Japan's aging population creates opportunities for implantable devices managing multiple chronic conditions simultaneously. Manufacturing capabilities in the region reduce production costs making devices more affordable. Regulatory authorities streamline approval processes attracting clinical trials and product launches. Hospital infrastructure investments support adoption of sophisticated implantable technologies requiring specialized facilities. Digital health initiatives integrate implantable devices with telemedicine platforms enabling remote monitoring.

Latin America Implantable Drug Delivery Devices Market Analysis

Latin America demonstrates increasing adoption driven by public health initiatives addressing chronic disease burdens. Brazilian research institutions partner with European companies advancing flow chemistry for device manufacturing. Local production capabilities reduce import dependencies making implantable devices more accessible. Government programs in Mexico and Colombia expand healthcare coverage including advanced medical devices. Private healthcare sectors in major cities adopt latest implantable technologies attracting medical tourism. Regulatory harmonization initiatives facilitate multi-country product registrations reducing market entry barriers. Academic institutions develop local expertise through international collaborations and training programs. Infrastructure improvements support distribution networks ensuring device availability in remote areas. Economic growth enables middle-class expansion increasing demand for quality healthcare including implantable solutions.

Middle East and Africa Implantable Drug Delivery Devices Market Analysis

Middle East markets advance through government visions prioritizing healthcare sector development and medical device manufacturing. Saudi Aramco's collaboration developing modular flow reactors demonstrates commitment to advanced technology adoption. Gulf countries invest heavily in healthcare infrastructure including specialized centers for device implantation. African markets show potential with South Africa leading adoption of implantable technologies through private healthcare. International partnerships bring expertise and investment supporting local capacity building initiatives. Medical training programs develop skilled healthcare professionals capable of managing complex implantable devices. Regulatory frameworks evolve to balance patient access with safety requirements for new technologies. Disease burden from diabetes and cardiovascular conditions drives demand for long-term therapeutic solutions.

Competitive Landscape:

The global implantable drug delivery devices market is highly competitive, with numerous key players focusing on technological advancements, strategic partnerships, and product innovation to enhance market position. For instance, in October 2024, Silo Pharma, Inc., a biopharmaceutical firm focused on designing drug delivery systems, announced positive results for its recent dissolution and sterilization tests of its new implant SP-26 ketamine-loaded, developed for fibromyalgia and chronic pain. These tests were carried out as per the development agreement with Sever Pharma Solutions. As these conditions become more widespread, the necessity for efficient and enduring treatment options is steadily increasing. Additionally, the market is influenced by increasing regulatory requirements, with manufacturers striving to meet stringent safety and quality standards. Competition is also shaped by pricing strategies, market penetration, and the ability to secure partnerships with healthcare providers and pharmaceutical companies to expand distribution channels globally.

The report provides a comprehensive analysis of the competitive landscape in the implantable drug delivery devices market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Boston Scientific Corporation
  • Delpor Inc.
  • Koninklijke DSM N.V.
  • Medtronic plc
  • Theragenics Corporation

Key Questions Answered in This Report

  • 1.How big is the implantable drug delivery devices market?
  • 2.What is the future outlook of implantable drug delivery devices market?
  • 3.What are the key factors driving the implantable drug delivery devices market?
  • 4.Which region accounts for the largest implantable drug delivery devices market share?
  • 5.Which are the leading companies in the global implantable drug delivery devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Implantable Drug Delivery Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Implantable Drug Eluting Stents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Implantable Contraceptive Drug Delivery Devices
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Implantable Intraocular Drug Delivery Devices
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Implantable Brachytherapy Seeds Devices
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Implantable Drug Delivery Pump Devices
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Biodegradable Implants
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Non-Biodegradable Implants
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Autoimmune Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Obstetrics and Gynecology
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Ambulatory Surgery Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Boston Scientific Corporation
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Delpor Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Koninklijke DSM N.V.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Medtronic plc
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Theragenics Corporation
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio

List of Figures

  • Figure 1: Global: Implantable Drug Delivery Devices Market: Major Drivers and Challenges
  • Figure 2: Global: Implantable Drug Delivery Devices Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Implantable Drug Delivery Devices Market: Breakup by Product Type (in %), 2025
  • Figure 5: Global: Implantable Drug Delivery Devices Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Implantable Drug Delivery Devices Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Implantable Drug Delivery Devices Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Implantable Drug Delivery Devices Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Implantable Drug Delivery Devices (Implantable Drug Eluting Stents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Implantable Drug Delivery Devices (Implantable Drug Eluting Stents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Implantable Drug Delivery Devices (Implantable Contraceptive Drug Delivery Devices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Implantable Drug Delivery Devices (Implantable Contraceptive Drug Delivery Devices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Implantable Drug Delivery Devices (Implantable Intraocular Drug Delivery Devices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Implantable Drug Delivery Devices (Implantable Intraocular Drug Delivery Devices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Implantable Drug Delivery Devices (Implantable Brachytherapy Seeds Devices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Implantable Drug Delivery Devices (Implantable Brachytherapy Seeds Devices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Implantable Drug Delivery Devices (Implantable Drug Delivery Pump Devices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Implantable Drug Delivery Devices (Implantable Drug Delivery Pump Devices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Implantable Drug Delivery Devices (Biodegradable Implants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Implantable Drug Delivery Devices (Biodegradable Implants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Implantable Drug Delivery Devices (Non-Biodegradable Implants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Implantable Drug Delivery Devices (Non-Biodegradable Implants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Implantable Drug Delivery Devices (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Implantable Drug Delivery Devices (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Implantable Drug Delivery Devices (Cardiovascular) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Implantable Drug Delivery Devices (Cardiovascular) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Implantable Drug Delivery Devices (Autoimmune Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Implantable Drug Delivery Devices (Autoimmune Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Implantable Drug Delivery Devices (Obstetrics and Gynecology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Implantable Drug Delivery Devices (Obstetrics and Gynecology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Implantable Drug Delivery Devices (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Implantable Drug Delivery Devices (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Implantable Drug Delivery Devices (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Implantable Drug Delivery Devices (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Implantable Drug Delivery Devices (Ambulatory Surgery Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Implantable Drug Delivery Devices (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Implantable Drug Delivery Devices (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Implantable Drug Delivery Devices (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: North America: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: North America: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: United States: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: United States: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Canada: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Canada: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Asia-Pacific: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Asia-Pacific: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: China: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: China: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Japan: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Japan: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: India: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: India: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: South Korea: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: South Korea: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Australia: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Australia: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Indonesia: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Indonesia: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Others: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Others: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Europe: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Europe: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Germany: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Germany: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: France: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: France: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: United Kingdom: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: United Kingdom: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Italy: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Italy: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Spain: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Spain: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Russia: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Russia: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Latin America: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Latin America: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Brazil: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Brazil: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Mexico: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Mexico: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Others: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Others: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Middle East and Africa: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Middle East and Africa: Implantable Drug Delivery Devices Market: Breakup by Country (in %), 2025
  • Figure 87: Middle East and Africa: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Global: Implantable Drug Delivery Devices Industry: Drivers, Restraints, and Opportunities
  • Figure 89: Global: Implantable Drug Delivery Devices Industry: Value Chain Analysis
  • Figure 90: Global: Implantable Drug Delivery Devices Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Implantable Drug Delivery Devices Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Implantable Drug Delivery Devices Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 3: Global: Implantable Drug Delivery Devices Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: Implantable Drug Delivery Devices Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Implantable Drug Delivery Devices Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Implantable Drug Delivery Devices Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Implantable Drug Delivery Devices Market: Competitive Structure
  • Table 8: Global: Implantable Drug Delivery Devices Market: Key Players